Technical Analysis for OPK - OPKO Health Inc.

Grade Last Price % Change Price Change
F 3.8 -5.00% -0.20
OPK closed down 5.0 percent on Friday, May 7, 2021, on 1.77 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical OPK trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -5.00%
Lower Bollinger Band Walk Weakness -5.00%
Stochastic Reached Oversold Weakness -5.00%
BB Squeeze + Lower Band Touch Range Contraction -5.00%
Lower Bollinger Band Touch Weakness -5.00%
Older End-of-Day Signals for OPK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 8 hours ago
Down 1 ATR about 8 hours ago
3x Volume Pace about 8 hours ago
2x Volume Pace about 8 hours ago
1.5x Volume Pace about 8 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


OPKO Health Inc. Description

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Pharmaceutical Products Cancers Prostate Cancer Autoimmune Disease Phosphate Chemotherapy Antibiotic Clinical Trial Small Cell Lung Cancer Non Small Cell Lung Cancer Influenza Ophthalmic Vitamin Alzheimer's Disease Dialysis Kidney Disease Thyroid Medical Tests Asthma Biomarker Diagnostic Tests Hormones Pancreatic Cancer Pulmonary Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Molecular Diagnostics Active Pharmaceutical Ingredients Antibiotics Hemodialysis Renal Disease Infectious Disease Biomarkers End Stage Renal Disease Oligonucleotide Stage Renal Disease Nausea Pathology Influenza Vaccine Metabolic Disorders Influenza Vaccines Vascular Products Chronic Obstructive Pulmonary Diseases Heart Disease Medical Laboratory Organ Failure Cardiovascular Products Hyperparathyroidism Heparin OLAP Opko Health Secondary Hyperparathyroidism Chemotherapy Induced Nausea Hyperphosphatemia

Is OPK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.47
52 Week Low 2.08
Average Volume 5,188,209
200-Day Moving Average 4.37
50-Day Moving Average 4.35
20-Day Moving Average 4.16
10-Day Moving Average 4.09
Average True Range 0.20
ADX 10.89
+DI 18.87
-DI 28.06
Chandelier Exit (Long, 3 ATRs ) 3.91
Chandelier Exit (Short, 3 ATRs ) 4.38
Upper Bollinger Band 4.45
Lower Bollinger Band 3.88
Percent B (%b) -0.13
BandWidth 13.79
MACD Line -0.12
MACD Signal Line -0.10
MACD Histogram -0.0241
Fundamentals Value
Market Cap 2.55 Billion
Num Shares 670 Million
EPS -0.42
Price-to-Earnings (P/E) Ratio -8.96
Price-to-Sales 2.52
Price-to-Book 1.91
PEG Ratio -2.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.04
Resistance 3 (R3) 4.06 3.99 4.00
Resistance 2 (R2) 3.99 3.93 3.99 3.99
Resistance 1 (R1) 3.90 3.89 3.87 3.88 3.97
Pivot Point 3.83 3.83 3.82 3.83 3.83
Support 1 (S1) 3.74 3.77 3.71 3.72 3.63
Support 2 (S2) 3.67 3.73 3.67 3.61
Support 3 (S3) 3.58 3.67 3.60
Support 4 (S4) 3.56